Cargando…
The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative
Drug induced liver injury (DILI) is a rare but well recognized serious adverse reaction. Pre-marketing studies may not detect liver injury, and DILI becomes very often apparent after the drug is launched to the market. Specific biomarkers for DILI prediction or diagnosis are not available. Toxic liv...
Autores principales: | Bessone, Fernando, Hernandez, Nelia, Lucena, M. Isabel, Andrade, Raúl J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813176/ https://www.ncbi.nlm.nih.gov/pubmed/26938524 http://dx.doi.org/10.3390/ijms17030313 |
Ejemplares similares
-
Nitrofurantoin-induced liver injury: long-term follow-up in two prospective DILI registries
por: Bessone, Fernando, et al.
Publicado: (2022) -
Biomarkers in DILI: One More Step Forward
por: Robles-Díaz, Mercedes, et al.
Publicado: (2016) -
Genetic variations in drug-induced liver injury (DILI): resolving the puzzle
por: Stephens, Camilla, et al.
Publicado: (2012) -
A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
por: Björnsson, Einar S., et al.
Publicado: (2022) -
Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice
por: Villanueva-Paz, Marina, et al.
Publicado: (2021)